PPARs and Liver Disease

PPARs and Liver Disease

Saved in:

Bibliographic Details
Main Authors:	Yasuteru Kondo, Kenji Uno, Keigo Machida, Masanori Terajima
Format:	Article
Language:	English
Published:	Wiley 2013-01-01
Series:	PPAR Research
Online Access:	http://dx.doi.org/10.1155/2013/896412
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Toll-Like Receptor Signaling in Liver Diseases
by: Gyongyi Szabo, et al.
Published: (2010-01-01)

PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs
by: Marion Peyrou, et al.
Published: (2012-01-01)

The Role of PPARs in Cancer
by: Keisuke Tachibana, et al.
Published: (2008-01-01)

PPAR and Liver Injury in HIV-Infected Patients
by: Maud Lemoine, et al.
Published: (2009-01-01)

PPARs in Viral Disease
by: Jacqueline Capeau, et al.
Published: (2009-01-01)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
by: Changxi Chen, et al.
Published: (2022-01-01)

PPARs in Lung Biology and Disease
by: Theodore J. Standiford, et al.
Published: (2007-01-01)

PPARs/RXRs in Cardiovascular Physiology and Disease
by: Brian N. Finck, et al.
Published: (2008-01-01)

IRF8 aggravates nonalcoholic fatty liver disease via BMAL1/PPARγ axis
by: Xinyue Li, et al.
Published: (2025-05-01)

Therapeutic Targeting of PPAR&gamma; in Nonalcoholic Fatty Liver Disease: Efficacy, Safety, and Drug Development
by: Zhou Z, et al.
Published: (2025-08-01)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
by: Luis A. Videla, et al.
Published: (2012-01-01)

Peroxisome Proliferator Activator Receptor (PPAR)-γ Ligand, but Not PPAR-α, Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver
by: Azza A. K. El-Sheikh, et al.
Published: (2014-01-01)

Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα
by: Guilin Ren, et al.
Published: (2025-05-01)

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
by: Alexandra Rogue, et al.
Published: (2010-01-01)

PPAR Medicines and Human Disease: The ABCs of It All
by: Anthony J. Apostoli, et al.
Published: (2012-01-01)

PPARS and Obesity
by: Francine M. Gregoire, et al.
Published: (2007-01-01)

Amelioration of High Fructose Diet-Induced Insulin Resistance, Hyperuricemia, and Liver Oxidative Stress by Combined Use of Selective Agonists of PPAR-α and PPAR-γ in Rats
by: Mahmoud M. Farag, et al.
Published: (2020-04-01)

Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments
by: Ayesheh Enayati, et al.
Published: (2022-01-01)

Genetic Manipulations of PPARs: Effects on Obesity and Metabolic Disease
by: Yaacov Barak, et al.
Published: (2007-01-01)

PPARs in Rhythmic Metabolic Regulation and Implications in Health and Disease
by: Purin Charoensuksai, et al.
Published: (2010-01-01)

Schisandrin B alleviates metabolic associated fatty liver disease by regulating the PPARγ signaling pathway and gut microbiota in mice
by: Jiuchen Wan, et al.
Published: (2025-07-01)

Genetic Variation of PPARs
by: Marie-Claude Vohl, et al.
Published: (2009-01-01)

PPAR in Cardiovascular Disorders
by: Alexander N. Orekhov, et al.
Published: (2016-01-01)

PPARs and Anticancer Therapies
by: Michael E. C. Robbins, et al.
Published: (2010-01-01)

Macrophages, PPARs, and Cancer
by: Jo A. Van Ginderachter, et al.
Published: (2008-01-01)

PPARs, Obesity, and Inflammation
by: Sander Kersten, et al.
Published: (2007-01-01)

PPARs and Bone Metabolism
by: Beata Lecka-Czernik
Published: (2006-01-01)

PPARs and Gastrointestinal Cancer
by: Valerio Pazienza
Published: (2012-01-01)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
by: Roberto Scatena, et al.
Published: (2008-01-01)

Metabolomics of the interaction between PPAR‐α and age in the PPAR‐α‐null mouse
by: Helen J Atherton, et al.
Published: (2009-04-01)

Toll-Like Receptors Signaling Contributes to Immunopathogenesis of HBV Infection
by: Yasuteru Kondo, et al.
Published: (2011-01-01)

Biological Significance of HCV in Various Kinds of Lymphoid Cells
by: Yasuteru Kondo, et al.
Published: (2012-01-01)

HLF and PPARα axis regulates metabolic‐associated fatty liver disease through extracellular vesicles derived from the intestinal microbiota
by: Xingzhen Yang, et al.
Published: (2025-04-01)

Utilizing computational approaches for the prediction of alpha-PPAR inhibitors from baobab (Adansonia digitata) against non-alcoholic fatty liver disease
by: Asia Awad AbdelGader, et al.
Published: (2024-12-01)

Fat-1 Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease and Atherosclerosis through Promoting the Nuclear Localization of PPARα in Hamsters
by: Wenxi Zhang, et al.
Published: (2025-01-01)

Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer’s Disease
by: Manoj Govindarajulu, et al.
Published: (2018-01-01)

MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers
by: Dorothea Portius, et al.
Published: (2017-01-01)

NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?
by: Gerardo G. Mackenzie, et al.
Published: (2008-01-01)

Exploring PPAR Gamma and PPAR Alpha’s Regulation Role in Metabolism via Epigenetics Mechanism
by: Małgorzata Małodobra-Mazur, et al.
Published: (2024-11-01)

Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells
by: Camilla Moliterni, et al.
Published: (2024-12-01)